Teva Pharmaceutical (TEVA) Tops Q4 EPS by 1c

Teva Pharmaceutical (NASDAQ: TEVA) reported Q4 EPS of $1.59, $0.01 better than the analyst estimate of $1.58. Revenue for the quarter came in at $5.68 billion versus the consensus estimate of $5.61 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c